

FLOWCHART OF AN EMBODIMENT OF THE CURRENT INVENTION




FIG. 1

OVERVIEW OF ANALYTICS PERFORMED WITH KMK917 WITH REGARD TO HINGE REGION MODIFICATION




FIG. 2

FIG. 3A CEx-HPLC of isolated KMK antibody samples




FIG. 3B CEx-HPLC of isolated KMK antibody samples – wild type




FIG. 3C CEx-HPLC of isolated KMK antibody samples – wild type




FIG. 3D CEx-HPLC of isolated KMK antibody samples – hinge mutant




FIG. 3E CEx-HPLC of isolated KMK antibody samples – hinge mutant




FIG. 3F CEx-HPLC of isolated KMK antibody samples – mutant (transgenic)




FIG. 3G CEx-HPLC of isolated KMK antibody samples – mutant (transgenic)




FIG. 4A CEx-HPLC of KMK wild type sample ± Endoglycosidase F treatment, wild type




FIG. 4B CEx-HPLC of KMK wild type sample ± Endoglycosidase F treatment, wild type




FIG. 4C CEx-HPLC of KMK mutant sample ± Endoglycosidase F treatment, hinge and CH2 mutant




FIG. 4D CEx-HPLC of KMK wild type sample ± Endoglycosidase F treatment, hinge and CH2 mutant






FIG. 5A**Carbohydrate pattern of KMK917****FIG. 5B****KMK917 2012/2014 hinge + Ch2 mutant (HT 5571_4)****FIG. 5C****KMK917, Full Scale**